Study Purpose:
The purpose of this study is to study use of advance Digital Health Technologies (DHT) and its validity as measures for assessing progression in Amyotrophic Lateral Sclerosis (ALS) patients. A total of 80 ALS patients will be recruited across US, and will involve two sites - St. Joseph Hospital and Medical Center in Phoenix, AZ, and Emory University ALS Clinic in Atlanta. This will be a fully remote observational study and will employ remote data collection platforms such as (a) A digital spirometry device powered by a mobile app will be used to measure vital capacity; (b) A clinical-grade voice recording app will be used to evaluate speech function; (c) A medical-grade wearable sensor will be used to monitor activity levels and sleep patterns; and (d) Standardized Electronic Clinical Outcome Assessments (eCOA) and Patient Reported Outcomes (ePRO) will be used to evaluate quality of life and cognitive abilities.The main goals of this study is to answer some of these questions:
1. Can ALS patients measure important aspects of disease progression at home, either by themselves with appropriate training or with assistance of a coordinators via virtual visit?
2. Which clinical outcome measures collected through DHT are sensitive indicators of ALS progression?
3. Are the measures reproducible and whether they can correlate with gold standard assessments?
The results of this study have the potential to provide valuable information for designing future ALS trials that are more decentralized, more patient-centric, and require less visits to the clinic which typically become a major burden with disease progression
Study Status:
Recruiting
Disease:
ALS (Amyotrophic Lateral Sclerosis)
Study Type:
Observational
Type of Intervention:
N/A
Intervention Name:
N/A
Placebo:
N/A
Phase:
N/A
Study Chair(s)/Principal Investigator(s):
N/A
Clinicaltrials.gov ID:
Neals Affiliated?
No
Coordinating Center Contact Information
Praveena Mohan, PhD / email hidden; JavaScript is required / 602-406-3032
Study Sponsor:
St. Joseph's Hospital and Medical Center, Phoenix
Estimated Enrollment:
80
Estimated Study Start Date:
02 / 21 / 2022
Estimated Study Completion Date:
03 / 01 / 2024
Posting Last Modified Date:
11 / 17 / 2022
Date Study Added to neals.org:
03 / 11 / 2022
Minimum Age:
18 Years
Maximum Age:
90 Years
Inclusion Criteria:1. Male or female, age 18 to 90.
2. Diagnosed with definite, probable, or possible ALS according to the modified El Escorial Criteria (EEC) or diagnosed with ALS using the Gold Coast Criteria.
3. Must be able to ambulate independently at the time of enrollment, with or without the use of foot braces or cane.
4. A vital capacity score of ≥40% of the predicted value (at last known in-person visit and if available).
5. Intelligible speech with occasional repetition.
6. Willingness and medical ability to comply with scheduled visits and study procedures.
7. Ability to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use protected health information (PHI).
8. Possession of a smartphone, and willingness to install study apps on it.
9. Continuous internet access at home, with stable broadband internet access.
10. Sufficiently proficient in English to understand and complete questionnaires and follow instructions using smartphone apps.
Exclusion Criteria:
1. Diagnosed with a superimposed medical condition that could confound study procedures in the opinion of the investigator.
2. Unwilling or unable to comply with the requirements of this protocol, including the presence of any condition (physical, mental, or social) that is likely to affect the participant's ability to comply with the protocol.
3. Any other reasons that, in the opinion of the PI, the candidate is determined to be unsuitable for entry into the study.
Barrow Neurological Institute | Recruiting
Praveena Mohan, PhD / 602-406-3032 / email hidden; JavaScript is required
Sub-Investigator : Bill Jacobsen, MD
Phoenix, Arizona
85013
United States
Emory University | Recruiting
Katherine Cummings / 602-406-6262 / email hidden; JavaScript is required
Principal Investigator : Jonathan D. Glass, MD
Atlanta, Georgia
30322
United States